Abstract As part of a research program to develop compounds with mixed dopamine D 4 and serotonin 5-HT 2A antagonist activity with potential for the treatment of schizophrenia, we report a family of compounds based on structural modification of the atypical antipsychotic, clozapine (2). The chemical synthesis, structural characterization and pharmacological evaluation of a series 4-arylmethyl analogues of clozapine are described. Preliminary ...